Merck woul_老虎社区_美港股上老虎

MrKeith
2021-12-11

Merck would be a better option comparing to Amgen. They diversified their products.

Is It Time to Buy the Dow's 3 Worst Performing Stocks This Year?

Take a look to see if these dogs of the Dow are worth buying.

Is It Time to Buy the Dow's 3 Worst Performing Stocks This Year?

免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。

推荐
最新

暂无评论

热议股票

关于我们·老虎社区守则·老虎社区账号管理规范·老虎社区服务协议·老虎社区隐私政策

公司名称：北京至简风宜信息技术有限公司

违法和不良信息投诉：010-5681-3562（工作时间9:30-18:30）

邮箱：service@laohu8.com

营业执照：91110105MA01A4U55R

ICP备：京ICP备18016422号

网安备：京公网安备11010502036490

关注我们

{"i18n":{"language":"zh_CN"},"data":{"magic":2,"id":605221230,"tweetId":"605221230","gmtCreate":1639183005832,"gmtModify":1639183005832,"author":{"id":4092093145464560,"idStr":"4092093145464560","authorId":4092093145464560,"authorIdStr":"4092093145464560","name":"MrKeith","avatar":"https://static.tigerbbs.com/460dea2188efdfc37ad3bbaf86f6b649","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":3,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":1,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body>Merck would be a better option comparing to Amgen. They diversified their products.&nbsp;</body></html>","htmlText":"<html><head></head><body>Merck would be a better option comparing to Amgen. They diversified their products.&nbsp;</body></html>","text":"Merck would be a better option comparing to Amgen. They diversified their products.","highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":2,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/605221230","repostId":1122303970,"repostType":4,"repost":{"id":"1122303970","kind":"news","pubTimestamp":1639135689,"share":"https://www.laohu8.com/m/news/1122303970?lang=&edition=full","pubTime":"2021-12-10 19:28","market":"us","language":"en","title":"Is It Time to Buy the Dow's 3 Worst Performing Stocks This Year?","url":"https://stock-news.laohu8.com/highlight/detail?id=1122303970","media":"Motley Fool","summary":"Take a look to see if these dogs of the Dow are worth buying.","content":"The&nbsp;Dow Jones Industrial Average&nbsp;is an index made up of 30 of the largest and most influential companies on U.S. stock exchanges. The index has historically returned around 7.5% each year, so being up over 15% makes 2021 a year to celebrate.\nNot every stock in the Dow Jones has performed well. The three stocks we'll discuss are all down and have been since the beginning of 2021, despite the index being up so much. We'll look at each one to determine whether they represent an opportunity or are down for a good reason.\n1. Amgen\nBiotech company&nbsp;Amgen&nbsp;has been down about 7% since the beginning of 2021. The company develops and sells drugs aimed at inflammation, cancer, bone health, heart disease, and more.\n<img src=\"https://static.tigerbbs.com/115c1a57215446a5a83d447ffbb995ca\" tg-width=\"2000\" tg-height=\"1333\" width=\"100%\" height=\"auto\">Image source: Getty Images.\nWhen a company invents a successful drug, its formula is patented, protecting it from direct competition for many years. Medications can cost millions of dollars to research and develop but can fail when tested in trials. A successful drug sometimes referred to as a blockbuster, can bring in billions in revenue over the length of its patent.\nInvestors can get a feel for the trajectory of a drug company by following when its key products lose their patent protection. Once this happens, generic competitors flood the market at lower prices, significantly reducing the original drug's sales.\nMany of Amgen's primary products could lose sales when their patents expire:\n<ul>\n <li>Enbrel (19% of revenue) expires in the U.S. in 2029.</li>\n <li>Prolia (12% of revenue) expires in the U.S. in 2025.</li>\n <li>Otezla (9% of revenue) expires in the U.S. in 2028.</li>\n <li>Xgeva (8% of revenue) expires in the U.S. in 2025.</li>\n</ul>\nThe United States has a more-complicated patent system, where drug companies can extend their patents by making minor changes to them. This, combined with the high drug prices charged in the U.S. market, is why domestic sales account for 68% of Amgen's global revenue. As these patents expire over the next decade, the company will&nbsp;need its pipeline to deliver&nbsp;successful products to replace this lost revenue.\nThe stock currently trades at a&nbsp;price-to-earnings ratio&nbsp;(P/E) of 12 using analyst estimates for 2021&nbsp;earnings per share&nbsp;(EPS), far less than its historical average of 17. Analysts are calling for growth of 8% per year over the next three to five years, and pharmaceutical companies face political pressure in the United States due to drug prices. These risks probably justify a discounted valuation, and that's just what the stock offers at these levels.\nVerdict: thumbs-up\n2. Merck\nA rival to Amgen,Merck&nbsp;develops drugs for cancer, immunology, and virology, as well as vaccine products, along with a separate business unit that develops drugs for veterinary use. The stock has maintained its 11% decline since the beginning of the year.\nMerck doesn't have a patent cliff that's quite as imminent as Amgen's. Its Januvia/Janumet accounts for about 10% of sales, and its patent expires in 2022, but the patents for the rest of Merck's significant drugs like Keytruda (34% of revenue) and Gardasil (15% of revenue) don't expire until 2028.\nThe company also released positive results from its clinical trials on molnupiravir, a pill that, when taken at the early stages of COVID-19 infection, can reduce the risk of serious illness by 30%. Merck has already agreed to sell more than $2.2 billion in treatments, so as the omicron variant continues to spread, it could give a spark to Merck's business. Rival&nbsp;Pfizer&nbsp;is also bringing a similar pill to market, but there could be&nbsp;enough demand for both to succeedhere.\nThe stock is trading at a P/E of 11, a significant discount to its historical P/E of 27. Analysts are calling for modest growth of 6% per year over the next three to five years, but that might be conservative due to COVID treatments. Investors might not be factoring in the potential business from the COVID pill, and the valuation markdown could provide a margin of safety.\nVerdict: thumbs-up\n3. Verizon Communications\nDown 14% year to date, telecom company&nbsp;Verizon Communications&nbsp;is among a select few companies that control the wireless networks in the United States. The infrastructure that supports our nationwide phone network costs billions of dollars and took years to build out, so there is a minor threat from outside competition, even with fierce competitors like&nbsp;AT&amp;T&nbsp;and&nbsp;T-Mobile.\nThe stock trades at a P/E of just over 9 based on 2021 EPS estimates. This is a bargain valuation if we look at its historical average, 14. While many would assume that 5G technology would unlock a lot of growth, Verizon has historically been a slow-growing business even with the emergence of 3G and 4G networks over time.\nAnalysts estimate the company's three-to-five-year EPS growth at around 3% annually. Defensive investors who want a solid dividend can benefit here: It pays a dividend that yields 5% and needs just half of its profits to afford that payment. Investors focused on total returns probably won't get excited about Verizon, even at this reduced valuation.\nVerdict: thumbs-down","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Is It Time to Buy the Dow's 3 Worst Performing Stocks This Year?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIs It Time to Buy the Dow's 3 Worst Performing Stocks This Year?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-10 19:28 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/12/10/is-it-time-to-buy-the-dow-jones-3-worst-performing/>Motley Fool</a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\nThe Dow Jones Industrial Average is an index made up of 30 of the largest and most influential companies on U.S. stock exchanges. The index has historically returned around 7.5% each year, so being up...\n\n<a href=\"https://www.fool.com/investing/2021/12/10/is-it-time-to-buy-the-dow-jones-3-worst-performing/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRK":"默沙东","VZ":"威瑞森","AMGN":"安进"},"source_url":"https://www.fool.com/investing/2021/12/10/is-it-time-to-buy-the-dow-jones-3-worst-performing/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1122303970","content_text":"The Dow Jones Industrial Average is an index made up of 30 of the largest and most influential companies on U.S. stock exchanges. The index has historically returned around 7.5% each year, so being up over 15% makes 2021 a year to celebrate.\nNot every stock in the Dow Jones has performed well. The three stocks we'll discuss are all down and have been since the beginning of 2021, despite the index being up so much. We'll look at each one to determine whether they represent an opportunity or are down for a good reason.\n1. Amgen\nBiotech company Amgen has been down about 7% since the beginning of 2021. The company develops and sells drugs aimed at inflammation, cancer, bone health, heart disease, and more.\nImage source: Getty Images.\nWhen a company invents a successful drug, its formula is patented, protecting it from direct competition for many years. Medications can cost millions of dollars to research and develop but can fail when tested in trials. A successful drug sometimes referred to as a blockbuster, can bring in billions in revenue over the length of its patent.\nInvestors can get a feel for the trajectory of a drug company by following when its key products lose their patent protection. Once this happens, generic competitors flood the market at lower prices, significantly reducing the original drug's sales.\nMany of Amgen's primary products could lose sales when their patents expire:\n\nEnbrel (19% of revenue) expires in the U.S. in 2029.\nProlia (12% of revenue) expires in the U.S. in 2025.\nOtezla (9% of revenue) expires in the U.S. in 2028.\nXgeva (8% of revenue) expires in the U.S. in 2025.\n\nThe United States has a more-complicated patent system, where drug companies can extend their patents by making minor changes to them. This, combined with the high drug prices charged in the U.S. market, is why domestic sales account for 68% of Amgen's global revenue. As these patents expire over the next decade, the company will need its pipeline to deliver successful products to replace this lost revenue.\nThe stock currently trades at a price-to-earnings ratio (P/E) of 12 using analyst estimates for 2021 earnings per share (EPS), far less than its historical average of 17. Analysts are calling for growth of 8% per year over the next three to five years, and pharmaceutical companies face political pressure in the United States due to drug prices. These risks probably justify a discounted valuation, and that's just what the stock offers at these levels.\nVerdict: thumbs-up\n2. Merck\nA rival to Amgen,Merck develops drugs for cancer, immunology, and virology, as well as vaccine products, along with a separate business unit that develops drugs for veterinary use. The stock has maintained its 11% decline since the beginning of the year.\nMerck doesn't have a patent cliff that's quite as imminent as Amgen's. Its Januvia/Janumet accounts for about 10% of sales, and its patent expires in 2022, but the patents for the rest of Merck's significant drugs like Keytruda (34% of revenue) and Gardasil (15% of revenue) don't expire until 2028.\nThe company also released positive results from its clinical trials on molnupiravir, a pill that, when taken at the early stages of COVID-19 infection, can reduce the risk of serious illness by 30%. Merck has already agreed to sell more than $2.2 billion in treatments, so as the omicron variant continues to spread, it could give a spark to Merck's business. Rival Pfizer is also bringing a similar pill to market, but there could be enough demand for both to succeedhere.\nThe stock is trading at a P/E of 11, a significant discount to its historical P/E of 27. Analysts are calling for modest growth of 6% per year over the next three to five years, but that might be conservative due to COVID treatments. Investors might not be factoring in the potential business from the COVID pill, and the valuation markdown could provide a margin of safety.\nVerdict: thumbs-up\n3. Verizon Communications\nDown 14% year to date, telecom company Verizon Communications is among a select few companies that control the wireless networks in the United States. The infrastructure that supports our nationwide phone network costs billions of dollars and took years to build out, so there is a minor threat from outside competition, even with fierce competitors like AT&T and T-Mobile.\nThe stock trades at a P/E of just over 9 based on 2021 EPS estimates. This is a bargain valuation if we look at its historical average, 14. While many would assume that 5G technology would unlock a lot of growth, Verizon has historically been a slow-growing business even with the emergence of 3G and 4G networks over time.\nAnalysts estimate the company's three-to-five-year EPS growth at around 3% annually. Defensive investors who want a solid dividend can benefit here: It pays a dividend that yields 5% and needs just half of its profits to afford that payment. Investors focused on total returns probably won't get excited about Verizon, even at this reduced valuation.\nVerdict: thumbs-down","news_type":1},"isVote":1,"tweetType":1,"viewCount":1085,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":["MRK"],"verified":2,"subType":0,"readableState":1,"langContent":"CN","currentLanguage":"CN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":71,"xxTargetLangEnum":"ZH_CN"},"commentList":[],"hasMoreComment":false,"orderType":2}

Is It Time to Buy the Dow's 3 Worst Performing Stocks This Year?

评论（2）

热议股票